Acorda Therapeutics Inc
NASDAQ: ACOR
ACOR Stock Chart and Intraday Price
ACOR Stock Data
Asset Type | Common Stock |
Exchange | NASDAQ |
Currency | USD |
Country | USA |
Sector | LIFE SCIENCES |
Industry | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Address | 420 SAW MILL RIVER ROAD, ARDSLEY, NY, US |
Fiscal Year End | December |
Latest Quarter | 2023-12-31 |
Market Cap | 2.47M USD |
Shares Outstanding | 1,242,100 |
ACOR Articles
Thursday’s top analyst upgrades and downgrades included Altria, Bill.com, Boot Barn, Camping World, Charter Communications, Coca-Cola and Jack in the Box.
Published:
Thursday's top analyst upgrades, downgrades and initiations included BankUnited, Caterpillar, Costco, eBay, Ford, Kellogg, Lyft, Microsoft and Oshkosh.
Published:
The top analyst upgrades, downgrades and initiations for Wednesday included Acorda Therapeutics, Activision Blizzard, Bloom Energy, Care.com, CBS, Deere and Ferrari.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday included Carbonite, Cleveland-Cliffs, Conoco, Costco, EA, Eli Lilly, HP, PepsiCo and Roku.
Published:
Last Updated:
Acorda Therapeutics shares dipped on Thursday after the company announced that the FDA would be delaying its Prescription Drug User Fee Act goal date for its review of the New Drug Application of...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Alarm.com, Biogen, Blue Apron, Cisco, Lowe's, Pandora Media and Waste Management.
Published:
Last Updated:
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include Cisco Systems, Dollar General, NetApp, Pandora Media, Procter & Gamble and Target.
Published:
Last Updated:
Acorda Therapeutics saw its shares drop sharply following an announcement that it had paused new enrollment in a long-term safety study. In a sense, Acorda has halted this trial.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Equifax, Mallinckrodt, Nabors, Qualcomm, Salesforce and Snap.
Published:
Last Updated:
Acorda Therapeutics saw its shares get crushed early on Tuesday after the firm received a Refusal to File letter from the FDA in regards to its New Drug Application for Inbrija.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday include AIG, Boeing, GameStop, Gilead Sciences, Starbucks, CIGNA, Ciena and Ferrari.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday include BBVA, Fossil, Procter & Gamble, T-Mobile, Under Armour and Universal Display.
Published:
Last Updated:
Shares of Acorda Therapeutics saw a hand gain in early trading on Thursday after the company reported results from its late-stage Parkinson’s trial.
Published:
Last Updated:
Monday’s top analyst upgrades, downgrades and initiations include Anadarko Petroleum, Bristol-Myers Squibb, Comcast, Walt Disney and Merck.
Published:
Last Updated: